Evaluation of the management of Clostridioides difficile infection as a risk factor for recurrence. A retrospective observational study
Authors:
- José Mª Barbero AllendeJAJosé Mª Barbero Allende
- Iván UreñaIUIván Ureña
- Leticia CañivanoLCLeticia Cañivano
- Sara GarcíaSGSara García
- Cristina PazCPCristina Paz
- Álvaro Olmo-RuilobaÁOÁlvaro Olmo-Ruiloba
- Koldo JauregiKJKoldo Jauregi
- Sandra CoronadoSCSandra Coronado
- Lucas López RequejoLRLucas López Requejo
- Laura PorcelLPLaura Porcel
- Verónica PereaVPVerónica Perea
- María IrigoyenMIMaría Irigoyen
Open Access
- 26 November 2024
- journal article
- abstracts
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (1) , 48-59
Abstract
Introduction. One of the main problems with Clostridioides difficile infection (CDI) is its tendency to recur. The objective of the study is to analyze which factors in the clinical management of CDI favor recurrence. Material and methods. This is a retrospective study conducted at the Hospital Universitario Príncipe de Asturias on cases of CDI between January 2021 and June 2023. Demographic variables, comorbidities, risk factors for recurrence, and treatments used for CDI were recorded. Non-optimal clinical management was defined as: not discontinuing treatment with proton pump inhibitors (PPIs) if the patient was on them, not discontinuing concomitant antibiotic treatments if the patient was on these, the use of metronidazole monotherapy in any case, or the use of standard-dose vancomycin if there were risk factors for recurrence. Results. A total of 327 cases were found in 256 patients. 69 patients died within 8 weeks after the episode (26.9%). Among the remaining 258 episodes, there were 68 recurrences (26.3%). Of these 68 recurrences, 63 cases received nonoptimal treatment (93.2%), compared to 112/190 (58.9%) among those who did not recur. In the multivariate analysis adjusted for confounding factors, patients who received optimal treatment had an 89% lower risk of recurrence compared to those who did not receive it (OR 0.1; p < 0.001). Conclusions. Reducing the use of PPIs and antibiotics and prioritizing more effective treatments against CDI could improve the recurrence rates of this infection.Keywords
This publication has 23 references indexed in Scilit:
- Impact of Clostridium difficile recurrence on hospital readmissionsAmerican Journal of Infection Control, 2015
- Coste de la diarrea asociada a Clostridium difficile en EspañaRevista Espanola de Salud Publica, 2013
- The economic burden of Clostridium difficileClinical Microbiology and Infection, 2012
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent InfectionsClinical Infectious Diseases, 2011
- The host immune response to Clostridium difficileJournal of Medical Microbiology, 2011
- Clinical Predictors and Risk Factors for Relapsing Clostridium difficile InfectionThe American Journal of the Medical Sciences, 2010
- Antibiotic-Associated DiarrheaNew England Journal of Medicine, 2002
- Asymptomatic Carriage ofClostridium difficileand Serum Levels of IgG Antibody against Toxin ANew England Journal of Medicine, 2000
- Review article: treatment of Clostridium difficile infection.Alimentary Pharmacology & Therapeutics, 1997
- Undescribed toxin in pseudomembranous colitis.BMJ, 1977